Design of Potential Anti-tumor PARP-1 Inhibitors by QSAR and Molecular Modeling Studies

Overview

Journal Mol Divers

Date 2020 Mar 7

PMID 32140890

Citations 7

Authors

Zeinab Abbasi-Radmoghaddam

Siavash Riahi

Sajjad Gharaghani

Mohammad Mohammadi-Khanaposhtanai

Affiliations

Soon will be listed here.

Abstract

Poly ADP-ribose polymerase-1 (PARP-1) inhibitors have been recognized as new agents for the treatment of patients with breast cancer type 1 (BRCA1) disorders. The quantitative structure-activity relationships (QSAR) technique was used in order to achieve the required medicines for anticancer activity easier and faster. In this study, the QSAR method was developed to predict the half-maximal inhibitory concentration (IC) of 51 1H-benzo[d]immidazole-4-carboxamide derivatives by genetic algorithm-multiple linear regression (GA-MLR) and least squares-support vector machine (LS-SVM) methods. Results in the best QSAR model represented the coefficient of leave-one-out cross-validation (Q ) = 0.971, correlation coefficient (R) = 0.977, Fisher parameter (F) = 259.016 and root mean square error (RMSE) = 0.095, respectively, which indicated that the LS-SVM model had a good potential to predict the pIC (9 - log(IC nM)) values compared with other modeling methods. Also, molecular docking evaluated interactions between ligands and enzyme and their free energy of binding were calculated and used as descriptors. Molecular docking and the QSAR study completed each other. The results represented that the final model can be useful to design some new inhibitors. So, the knowledge of the QSAR modeling and molecular docking was used in pIC prediction and 51 new compounds were developed as PARP-1 inhibitors that 9 compounds had the best-proposed values for pIC. The maximum enhancement of the inhibitory activity of compounds was 33.394%.

Citing Articles

De Novo Design of Imidazopyridine-Tethered Pyrazolines That Target Phosphorylation of STAT3 in Human Breast Cancer Cells.

Ravish A, Shivakumar R, Xi Z, Yang M, Yang J, Swamynayaka A Bioengineering (Basel). 2023; 10(2).

PMID: 36829653 PMC: 9952374. DOI: 10.3390/bioengineering10020159.

PARP1pred: a web server for screening the bioactivity of inhibitors against DNA repair enzyme PARP-1.

Lerksuthirat T, Chitphuk S, Stitchantrakul W, Dejsuphong D, Malik A, Nantasenamat C EXCLI J. 2023; 22:84-107.

PMID: 36814851 PMC: 9939779. DOI: 10.17179/excli2022-5602.

Opportunities and challenges in application of artificial intelligence in pharmacology.

Kumar M, Nguyen T, Kaur J, Singh T, Soni D, Singh R Pharmacol Rep. 2023; 75(1):3-18.

PMID: 36624355 PMC: 9838466. DOI: 10.1007/s43440-022-00445-1.

A multi-task FP-GNN framework enables accurate prediction of selective PARP inhibitors.

Ai D, Wu J, Cai H, Zhao D, Chen Y, Wei J Front Pharmacol. 2022; 13:971369.

PMID: 36304149 PMC: 9592829. DOI: 10.3389/fphar.2022.971369.

Comparative differential cytotoxicity of clinically used SERMs in human cancer lines of different origin and its predictive molecular docking studies of key target genes involved in cancer progression and treatment responses.

S L, A S, Dv S, Bs R, R S, Sharaf S Curr Res Pharmacol Drug Discov. 2022; 3:100080.

PMID: 35059624 PMC: 8760488. DOI: 10.1016/j.crphar.2021.100080.

References

Sharma B, Kaur R, Raut S, Munshi A . BRCA1 mutation spectrum, functions, and therapeutic strategies: The story so far. Curr Probl Cancer. 2018; 42(2):189-207. DOI: 10.1016/j.currproblcancer.2018.01.001. View

Song D, Huang H, Wang J, Zhao Y, Hu X, He F . NF90 regulates PARP1 mRNA stability in hepatocellular carcinoma. Biochem Biophys Res Commun. 2017; 488(1):211-217. DOI: 10.1016/j.bbrc.2017.05.037. View

Zhou J, Ji M, Zhu Z, Cao R, Chen X, Xu B . Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity. Eur J Med Chem. 2017; 132:26-41. DOI: 10.1016/j.ejmech.2017.03.013. View

Park S, Noh S, Kim K, Bae J, Kwon K, Jung S . Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients. Transl Oncol. 2015; 8(4):239-49. PMC: 4562981. DOI: 10.1016/j.tranon.2015.04.004. View

Rabenau K, Hofstatter E . DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics. Clin Ther. 2016; 38(7):1577-88. DOI: 10.1016/j.clinthera.2016.06.006. View

Aouidate A, Ghaleb A, Ghamali M, Ousaa A, Choukrad M, Sbai A . 3D QSAR studies, molecular docking and ADMET evaluation, using thiazolidine derivatives as template to obtain new inhibitors of PIM1 kinase. Comput Biol Chem. 2018; 74:201-211. DOI: 10.1016/j.compbiolchem.2018.03.008. View

Chen M, Yang X, Lai X, Gao Y . 2D and 3D QSAR models for identifying diphenylpyridylethanamine based inhibitors against cholesteryl ester transfer protein. Bioorg Med Chem Lett. 2015; 25(20):4487-95. DOI: 10.1016/j.bmcl.2015.08.080. View

Liu Z, Liu Y, Zeng G, Shao B, Chen M, Li Z . Application of molecular docking for the degradation of organic pollutants in the environmental remediation: A review. Chemosphere. 2018; 203:139-150. DOI: 10.1016/j.chemosphere.2018.03.179. View

Kramer V, Giesy J . Specific binding of hydroxylated polychlorinated biphenyl metabolites and other substances to bovine calf uterine estrogen receptor: structure-binding relationships. Sci Total Environ. 1999; 233(1-3):141-61. DOI: 10.1016/s0048-9697(99)00221-1. View

10.

Dai Y, Wang Q, Zhang X, Jia S, Zheng H, Feng D . Molecular docking and QSAR study on steroidal compounds as aromatase inhibitors. Eur J Med Chem. 2010; 45(12):5612-20. DOI: 10.1016/j.ejmech.2010.09.011. View

11.

Ihmaid S, Ahmed H, Ali A, Sherif Y, Tarazi H, Riyadh S . Rational design, synthesis, pharmacophore modeling, and docking studies for identification of novel potent DNA-PK inhibitors. Bioorg Chem. 2017; 72:234-247. DOI: 10.1016/j.bioorg.2017.04.014. View

12.

Pourbasheer E, Riahi S, Ganjali M, Norouzi P . Application of genetic algorithm-support vector machine (GA-SVM) for prediction of BK-channels activity. Eur J Med Chem. 2009; 44(12):5023-8. DOI: 10.1016/j.ejmech.2009.09.006. View

13.

Basant N, Gupta S, Singh K . Predicting aquatic toxicities of chemical pesticides in multiple test species using nonlinear QSTR modeling approaches. Chemosphere. 2015; 139:246-55. DOI: 10.1016/j.chemosphere.2015.06.063. View

14.

Roy K, Roy P . Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques. Eur J Med Chem. 2009; 44(7):2913-22. DOI: 10.1016/j.ejmech.2008.12.004. View

15.

Laskowski R, Swindells M . LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model. 2011; 51(10):2778-86. DOI: 10.1021/ci200227u. View

16.

Daina A, Zoete V . A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. ChemMedChem. 2016; 11(11):1117-21. PMC: 5089604. DOI: 10.1002/cmdc.201600182. View

17.

Fernandez M, Caballero J . QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives. Bioorg Med Chem. 2007; 15(18):6298-310. DOI: 10.1016/j.bmc.2007.06.014. View

18.

Gharaghani S, Khayamian T, Ebrahimi M . Molecular dynamics simulation study and molecular docking descriptors in structure-based QSAR on acetylcholinesterase (AChE) inhibitors. SAR QSAR Environ Res. 2013; 24(9):773-94. DOI: 10.1080/1062936X.2013.792877. View

19.

Nantasenamat C, Monnor T, Worachartcheewan A, Mandi P, Isarankura-Na-Ayudhya C, Prachayasittikul V . Predictive QSAR modeling of aldose reductase inhibitors using Monte Carlo feature selection. Eur J Med Chem. 2014; 76:352-9. DOI: 10.1016/j.ejmech.2014.02.043. View